Markets
News
Analysis
User
24/7
Economic Calendar
Education
Data
- Names
- Latest
- Prev
- Trade
- Markets
- Copy
- Contests
- News
- 24/7
- Calendar
- Q&A
- Chats
Trending
SYMBOL
LAST
BID
ASK
HIGH
LOW
NET CHG.
%CHG.
SPREAD
SPX
S&P 500 Index
6870.39
6870.39
6870.39
6895.79
6858.28
+13.27
+ 0.19%
--
DJI
Dow Jones Industrial Average
47954.98
47954.98
47954.98
48133.54
47871.51
+104.05
+ 0.22%
--
IXIC
NASDAQ Composite Index
23578.12
23578.12
23578.12
23680.03
23506.00
+72.99
+ 0.31%
--
USDX
US Dollar Index
98.920
99.000
98.920
98.960
98.730
-0.030
-0.03%
--
EURUSD
Euro / US Dollar
1.16486
1.16493
1.16486
1.16717
1.16341
+0.00060
+ 0.05%
--
GBPUSD
Pound Sterling / US Dollar
1.33210
1.33217
1.33210
1.33462
1.33136
-0.00102
-0.08%
--
XAUUSD
Gold / US Dollar
4205.38
4205.81
4205.38
4218.85
4190.61
+7.47
+ 0.18%
--
WTI
Light Sweet Crude Oil
59.310
59.340
59.310
60.084
58.980
-0.499
-0.83%
--
- All
- Chatrooms
- Groups
- Friends
Connecting
.
.
.
- All
- Russia-Ukraine Conflict
- Middle East Flashpoint
ANAB: Separation of royalty and biopharma units in 2026 aims to unlock value and advance key clinical assets
Quartr
Plans are underway to split the royalty and biopharma businesses in 2026, with each designed for independent resilience. ANB033 and Rosnilimab are advancing in clinical development, while the royalty business expects strong cash flow and ongoing litigation with GSK is not expected to impact operations.
Based on AnaptysBio, Inc. [ANAB] Evercore ISI 8th Annual HealthCONx Conference Audio Transcript — Dec. 3 2025
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Risk Warnings and Disclaimers
You understand and acknowledge that there is a high degree of risk involved in trading. Following any strategies or investment methods may lead to potential losses. The content on the site is provided by our contributors and analysts for information purposes only. You are solely responsible for determining whether any trading assets, securities, strategy, or any other product is suitable for investing based on your own investment objectives and financial situation.
Copyright © 2025 FastBull Ltd
728 RM B 7/F GEE LOK IND BLDG NO 34 HUNG TO RD KWUN TONG KLN HONG KONG
Risk Disclosure
The risk of loss in trading financial instruments such as stocks, FX, commodities, futures, bonds, ETFs and crypto can be substantial. You may sustain a total loss of the funds that you deposit with your broker. Therefore, you should carefully consider whether such trading is suitable for you in light of your circumstances and financial resources.
No decision to invest should be made without thoroughly conducting due diligence by yourself or consulting with your financial advisors. Our web content might not suit you since we don't know your financial conditions and investment needs. Our financial information might have latency or contain inaccuracy, so you should be fully responsible for any of your trading and investment decisions. The company will not be responsible for your capital loss.
Without getting permission from the website, you are not allowed to copy the website's graphics, texts, or trademarks. Intellectual property rights in the content or data incorporated into this website belong to its providers and exchange merchants.
Not Logged In
Log in to access more features
FastBull Membership
Not yet
Purchase
Become a signal provider
Help Center
Dark Mode
Price Up/Down Colors
Log In
Sign Up